Skip to main content

2024 ACDIS Pocket Guide Excerpt - Bronchitis

Page 1

nchitis/COPD

2023 ACDIS POCKET GUIDE EXCERPT

y Compliance LLC

MDC 4

Bronchitis/COPD

Treatment The early stages of COPD may require no treatment besides efforts to limit contributing environmental factors. As the disease progresses, patients are often prescribed a combination of therapies, including oral/ inhaled steroids and bronchodilators (albuterol, ipratropium inhalers). Home oxygen may be provided for those in advanced stages. If the patient presents in an acute exacerbation, intervention could include oxygen saturations, arterial blood gases (ABG) monitoring, oxygen therapy including continuous positive airway pressure (CPAP), or ventilatory support depending on the severity. Antibiotics are usually prescribed to treat an identified infection or for prophylaxis. A pulmonary consult may be ordered.

Coding considerations The codes in category J44 (COPD) distinguish between uncomplicated cases and those in acute exacerbation (CC). Documentation should support a level of severity matching the clinical situation. If asthma is also documented as present, see Asthma. The J44 code grouping includes a “use additional code” note to identify tobacco dependence (F17.-) and tobacco use (Z72.0). Documentation of “smoker’s cough” is classified to J41.0, Simple chronic bronchitis. This code impacts CMS- and HHS-HCC risk adjustment as well as hospital mortality and quality metrics. Assign codes U07.1, and J20.8, Acute bronchitis due to other specified organisms for a patient with acute bronchitis confirmed as due to COVID-19. Bronchitis, not otherwise specified (NOS), due to COVID-19 should be coded using code U07.1 and J40, Bronchitis, not specified as acute or chronic.

© HCPro, a division of Simplify Compliance LLC

169


Turn static files into dynamic content formats.

Create a flipbook
2024 ACDIS Pocket Guide Excerpt - Bronchitis by ACDIS - Issuu